Slenyto Treatment Algorithm for Insomnia in Children with ASD and / or Neurogenetic Disorders (NGD
This treatment decision algorithm allows healthcare professionals to personalise titration of Slenyto to optimal dose.
Treatment success is attained by achieving one or more of the following:
- total sleep time within the recommended range for the subject’s age
- sleep onset <30 minutes
- longest sleep episode >6 hours
LSE, Longest Sleep Episode; SOL, Sleep Onset Latency; TST, Total Sleep Time.
Treatment Success Criteria1
• TST within the recommended range for the subject’s age
– 10–13 hours for age 3– 5 years
– 9–11 hours for ages 6–13 years
– 8–10 hours for ages 14–17 years
• SOL <30 minutes
• LSE >6 hours
For some people an additional hour or two on either side of a given range may be appropriate.
TST within the following range may be appropriate for the subject’s age2
– 8–14 hours for age 3–5 years
– 7–12 hours for ages 6–13 years
– 7–11 hours for ages 14–17 years
Related Resources
Watch our on-demand, where Dr Dara O’Donoghue provided an update on paediatric sleep disorders, including the evidence for pharmacological treatment of insomnia, and explored the diagnosis and management of restless leg syndrome and narcolepsy in children.
Watch this ASD vs ADHD webinar, where Dr Nagy Awadalla explores practical, evidence-informed approaches to supporting, managing, and treating individuals with ASD and ADHD. Centred around why accurate assessment of the conditions is essential for appropriate diagnosis, support planning and long-term outcomes, Dr Awadalla discussed the differences and the areas of overlap in the symptoms of individuals with ASD and ADHD.
Watch our on-demand study day featuring expert speakers Dr Mischa Mockett, Paula Chilcott, Dr Syed Naqvi, Dr Will Daw and Mr John Bulwich. The study day covers current approaches to the assessment, diagnosis and treatment of ADHD, the link between ADHD and addiction, the critical transition from adolescence to adulthood, and strategies for managing sleep in children with neurodevelopmental conditions.
A training resource for psychiatrists to facilitate identification of adult ADHD. Flynn Pharma, in conjunction with Virtual Health Shed, has developed 3D characters in a virtual environment to simulate interaction between the learner and a virtual patient or clinical virtual actor (avatar).
Despite its prevalence, ADHD in adults often goes unrecognised and remains under-diagnosed.
Tips leaflet for parents of children with ADHD affected by bullying. The leaflet discusses how to identify and deal with the impact of bullying.
This leaflet is a guide on safe driving, explaining ADHD and the risks, DVLA requirements, medication effects and tips on practical safety.
Tips on breakfast preparation, healthy diet and why it’s the most important meal of the day.
A short story which provides some useful insight into ADHD in girls. The book aims to improve self-esteem and confidence.
A fictional story about the importance of sleep aimed at children with ASD and ADHD aged 7 -11 years.
References
- Schroder M, et al. Paediatric Prolonged Release Melatonin for Insomnia in Children and Adolescents with Autistic Spectrum Disorder. Expert Opin Pharmacother. 2021;22(18)2445–54.
- National Sleep Foundation. https://www.thensf.org/how-many-hours-of-sleep-do-you-really-need/ (Accessed December 2024).
